Patent details

91122 Product Name: Efalizumab et ses dérivés pharmaceutiquement acceptables (RAPTIVA®)

Basic Information

Publication number:
91122
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP979128410
Legal Status:
Expired
Application number:
91122
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/04/291/001
Marketing Authorization Type:
Marketing Authorization Date:
20/09/2004
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
10/11/2004
First Marketing Authorization date:
20/09/2004
Grant date:
10/01/2005
Activation date:
20/10/2017
Publication date:
10/01/2005
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
20/09/2019
SPC Extension Expiration:
20/09/2019
Rejection date:
Withdrawal date:

Owner

From:
10/11/2004
 
 

Name:
Genentech Inc.
Address:
1 DNA Way, South San Francisco, CA 94080-4990, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
10/11/2004
Address:
PO Box 48, 8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
PRESTA Leonard, G.
Address:
United States (US)

2

Name:
JARDIEU Paula, M.
Address:
United States (US)

Publication

Bulletin

Bulletin Heading:
SPC3
Bulletin edition number:
2017/07
Publication date:
11/12/2017
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
04/10/2018
Last Annual Fee Paid Number:
22
Last Annual Fee Paid Amount:
420 Euro
Payer:
MDC (HENKEL PATENT)
Filing date Document type Number of pages